Since 2015, several new brands have launched in the United States for the treatment of motor and nonmotor symptoms in Parkinson’s disease (PD), and yet more are on the near-term horizon. Chronic polypharmacy and progressive disease pathology already drive a sizeable cost burden for elderly patients and payers; a growing population and the coming wave of premium-priced brands will exacerbate these market conditions. Anticipating payers’ receptivity to emerging products—some of which could be paradigm-altering—and how future coverage policies could affect patient access and neurologists’ treatment choice is crucial for drug developers entering an increasingly crowded, largely generic, and clinically complex market.

Questions Answered

  • What is the current state of coverage for key PD brands in the U.S. market? What restrictions do payers impose, and how do market access dynamics influence surveyed neurologists’ prescribing?
  • How receptive are payers to late-phase emerging therapies? What coverage decisions do they anticipate? How do neurologists expect to prescribe the agents?
  • What actions can developers take to optimize market access?

Markets covered: United States.

Primary research: Survey of 102 U.S. neurologists and 32 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).

Key drugs covered: AP-CD/LD, APL-130277, Apomorphine pump, Duopa, Gocovri, Inbrija, IPX-203, ND-0612, Nuplazid, Northera, Ongentys, Osmolex ER, Rytary, Xadago.

Product Description

U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Parkinson's Disease - Access & Reimbursement (US) - Report

Author(s): Bethany Christmann, PhD

Bethany Christmann, has been with DRG since 2015, and is a Senior Business Insights Analyst with the Central Nervous System/Ophthalmology team. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, Bethany earned her in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.


Related Reports

Parkinson's Disease | Landscape & Forecast | Disease Landscape & Forecast

The Parkinson’s disease (PD) therapy market is in the midst of transformation: the first new levodopa formulation (Rytary) in over a decade launched...

View Details

Parkinson's Disease | Executive Insights | Executive Insights (US)

Parkinson’s disease (PD) is predominantly recognized as a motor disorder, but PD is also associated with a diverse mix of disabling nonmotor symptoms, including cognitive impairment and dem...

View Details

Parkinson's Disease | Special Topics | Detailed, Expanded Analysis: Special Topics: Opportunity for Nonmotor Symptoms (US)

Coming Soon – June 2019 Parkinson’s disease (PD) is widely recognized as a motor disorder, but

View Details

Parkinson's Disease | Unmet Need | Detailed, Expanded Analysis - Levodopa-Induced Dyskinesia (US&EU)

As the term implies, levodopa-induced dyskinesia (LID) is a complication of chronic use of levodopa, the goldstandard of Parkinson’s disease...

View Details